NeuroSense Therapeutics Ltd. (NRSN): Cash & Equivalents
$166.0K
As of 2025-12-31
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $166.0K | -95.1% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $3.38M | +28.0% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $2.64M | n/a | 2025-04-07, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | 2025-12-31 | $166.0K | -95.1% |
| Semnur Pharmaceuticals, Inc. (SMNR) | 2025-12-31 | $20.0K | +66.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $251.3K | -18.3% |
| Alzamend Neuro, Inc. (ALZN) | 2026-04-30 | $710.7K | -82.0% |
| Bio Essence Corp (BIOE) | 2024-12-31 | $1.4K | n/m |
| Inhibitor Therapeutics, Inc. (INTI) | 2025-12-31 | $2.38M | -57.6% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $1.11M | -27.9% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $2.18M | -33.7% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $132.2K | n/m |
Compare NRSN, SMNR, PVCT, ALZN side by side · Screen every company in Pharmaceutical Preparations ↗